First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
Yaël C. Cohen(Sheba Medical Center), Hila Magen(Sheba Medical Center), Michael Chu(University of Michigan), Melissa Beelen(Janssen (United States)), María‐Victoria Mateos(Hospital Clínico San Carlos), Jill Vanak(Sheba Medical Center), Michelle R. Peterson(Sheba Medical Center), Albert Oriol(Institut Català d'Oncologia), Arnob Banerjee(Johnson & Johnson (United States)), Michaël Sébag(Sheba Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Paula Rodríguez‐Otero(Clinica Universidad de Navarra), Maria Krevvata(Janssen (United States)), Kihyun Kım(State University of New York), Yue Guo(Janssen (United States)), Daniel Morillo(Sheba Medical Center), Sung‐Soo Yoon(Seoul National University Hospital), Moshe E. Gatt(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Chang‐Ki Min(The Catholic University of Korea Seoul St. Mary's Hospital), Enrique M. Ocio(Universidad de Salamanca)
Cited by 88
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k